STRATEGIC

INVESTMENT
OPPORTUNITY
 ABOUT SUSAAH
SUSAAH LABORATORIES PRIVATE LIMITED was
incorporated as private limited company under
companies Act, 1956 at Hyderabad in the state of
Andhra Pradesh, India. The company is engaged
in the manufacturing of Active Pharmaceutical
Ingredients and Intermediates for catering to the
domestic as well as international market

SRINIVAS KANCHARLA is a Postgraduate degree holder in Organic Chemistry. He

worked in prestigious companies called M/s. Dr Reddy Laboratories Limited, M/s
Sanochemia (Europe-based), M/s Krebs Bio Chemicals Limited and M/s Liquors
India Limited. He is a 54-year-old dynamic, dedicated, hard-working nature and
has a good Vision.

Having a good and idealistic career, he established his career’s the Flagship
company’ M/s Sanova Pharmaceuticals Private Limited’ to carry on the business
of Agro-based pharma products. He is having 33 years of experience in the field of
Chemicals and Bulk Drugs.
SRINIVAS KANCHARLA .
His will of becoming ‘Business Pride’ for Andhra and Telangana States, insisted him to form this company,
M/s.Susaah Laboratories Private Limited, which most of the top industrialists followed the same entrance in their
career. The main objective of the company is to manufacture bulk drugs. His market knowledge, excellent
Management skills, Excellent vision, Right Decision making, dedication to work, Co-ordination of a Team,
Development of work and workforce, and Preparation of successful company policies and strategies will surely
help the company in making company ‘THE FIRST’ and ‘THE BEST’ always. He believes in ‘DARE TO DREAM AND
STRIVES TO ACHIEVE’

VISION MISSION VALUES

A preferred partner for the To develop and manufacture World Class Performance |
global pharmaceuticals industry active pharmaceutical Respect for Environment |
and share responsibilities for the ingredients (APIs) and C o h e s i v e Te a m - w o r k |
enhancement of human health intermediates for global supply, Innovative Culture | Quality
complying with quality and Consciousness |
regulatory requirements Collaborative Approach
 BUSINESS MODEL
Advance Intermediates and APIs
Manufacturing

New/Complex Product Development

and Manufacturing

Contract Research and Manufacturing

Services (CRAMS)

MANUFACTURING CAPABILITIES

Advanced
Intermediates

APIs

Polymorphs Screening & SUSAAH

Genotoxic Evaluation Laboratories

Analytical Method
Development & Quality
Assurance

Drug Master File

Preparation
End to end manufacturing capabilities for your rapid Filings…
 CHEMISTRY CAPABILITIES

Suzuki and Other couplings Catalysis

Cyclization's Bromination

Amination & Amidation reaction Chlorination

Cryogenic Reactions Nitration

Heterogeneous reactions Sulphonation

Metal Coupling reactions Alkylation

Pyrophoric reagents Cyanation

Chiral chemistry Grignard

Lithiation Reactions (n-BuLi) Peptide Coupling

 CLASS OF PRODUCTS OFFERED COMMERCIAL PRODUCTS LIST

Active Pharmaceutical ¤ Risedronate Sodium

1 Ingredients
¤ Biperidine HCl
Advanced Intermediates
2 (Advanced Intermediates for Clinical Candidates) ¤ Tamsulosin HCl

Intermediates / Regulatory ¤ Fluticasone Propionate

3 Starting Materials
¤ Etorocoxib
4 Key Starting Materials

5 Specialty Products

MANUFACTURING UNIT

ü Plant Area: ~12000 SQM / 3.0 Acres

ü Reactors: 15+

ü Clean Room for APIs

ü Intermediate Production Block

ü Capacity available for expansion

(30% as of now)
 ANALYTICAL FACILITY

HPLC : 16 (UV/ DAD/PDA, ELSD & RI)

LC-MS/MS : 02
Ion Chromatography (Metrohm): 01
PuriFlash (Preparative cum Flash): 01
GC-with FID : 02
Client Server : Lab Solutions CS
PSD Malvern Mastersizer 3000: 01
FTIR with ATR : 01
UV/VIS Spectrophotometer : 01
Temp/Humidity Chambers : 04
Photo stability chamber : 01
Dissolution Apparatus- : 04
KF Titrator & Potentiomer : 01
Polarimeter : 01
Flame Photometer : 01 State-of-the art Analytical and Bio-analytical facility*
Viscometer : 01 with well-qualified & experienced team

Auditable Analytical Services Partner

QUALITY ASSURANCE
¤ To meet the standards that our customers expectations.

¤ Implement internationally benchmarked QMS (quality

management systems)

¤ Employees are committed to quality culture

¤ Implementing good documentation process

¤ Quality assurance (QA) implementing uniform

standards across the organization on quality control,
quality compliance, training, turnaround time, quality by
design. Electronic quality, Vendor qualification,
information services, Annual Product Quality Review,
Product release and self inspections
PPEs | ZLD Facility | Green Practices | Emergency Exists
Fire Hydrant System | Separate Solvent Yard

Central Pollution Control Board (CPCB) Approval for the

facility | Waste/Effluent Disposal Mechanisms in place

All the chemists are trained with general laboratory safety

guidelines at the time of induction

Labs are equipped with fire extinguishers, sand buckets,

eye washers etc., and also under video surveillance

All the chemists are given Lab coats, Safety glasses, Gloves, Safety shields are used
for hazardous reactions and high temp reactions | Safety manual is kept in the labs
| All the liquid waste is segregated as chlorinated / non- chlorinated types

Solid waste segregation | Continuous training on

Safety to employees

R&D PARTNER
Team: 20+Years Experienced Professionals Leading Product Development & CRAMS; Post-doctoral &
Doctoral Fellows from Reputed Institutes; Talented & Experienced Masters’ Chemists/ Process
Engineers; Well-established Cross Functional Teams to deliver Products on Time

Facility: State-of-the Art R&D Facility (25,000 Sft) /

30+ Research Fume Hoods – Ambient working CUSTOM
Space for R&D / Kg scale production SYNTHESIS
CROSS
Pilot Scale Set-up: Well Equipped with Process CONTRACT COUPLING
Engineering Set-up; All Glass & SS Reactors – 630L, RESEARCH REACTIONS
200L, 100L & 50L
R&D
Spacious Ware House with Cold Storage Facility EXPERTISE
R&D Partner is committed for Quality, IP & CONTRACT MATERIAL
Confidentiality MANUFACTURING CHEMISTRY
R&D Partner is having Sci-Finder / Reaxys search
data base online journals
NATURAL PRODUCTS PEPTIDE
ANALOGOUS CHEMISTRY
 ONE-STOP SOLUTION FOR
MANUFACTURING

1 3
Kg Scale
@ @
R&D
Validations Manufacturing
Labs Site

2
@
Proof of Concept & Pilot Scale Production in
Process Development Lab 100Kg - MTs

WHY
SUSAAH
We are the experts in manufacturing
pharmaceuticals. We have the facilities,
systems and work-flows in place to support

High Value & Low Volume Contract Research & Early Phase & Late
APIs Manufacturing Development API Manufacturing

Well Integrated Team - R&D Quality and

to Commercial Production On Time Delivery
 SWOT ANALYSIS

S
Strengths
W
Weakness
O
Opportunities
T
Threats

¤ Cost effective ¤ Compliance to ¤ Enhance sales channel ¤ Competition

process principles ¤ Mapping production ¤ Commodication
¤ Oriented services ¤ Brand position ¤ Counterfeit drugs
¤ Quality Standards
¤ Imitate Business Model ¤ Community Relations ¤ Government
¤ Stability Chambers
¤ Supply & operation risk Intervention
¤ Manufacturing sites

COMPANY'S OPERATIONAL OVERVIEW WITH MARKET POSITION

The Indian healthcare sector is one of the fastest-growing sectors and is expected to cross US$ 375 Billion by
2022.India's domestic pharmaceutical market stood at US$ 42 billion in 2021 and is likely to reach US$ 65 billion
by 2024 and further expand to reach US$ 120-130 billion by 2030. Susaah is a pharma company which deals
with CRAMS, KSMs, speciality chemicals and APIs.
List of API's-
Etoricoxib Sitagliptin Raltegravir / elvitegravir Caftors (Tezacaftor,
Tamsulosin Biperiden Hcl / Dolutegravir Ivacaftor,Lumacaftor)
Risedronate Sodium Empagliflozin Apixaban Acyclovir ; Valacyclovir,
Fluticasone Siponimod Brivaracetam Abacavir.

Major Segments- Major products includes CRAMS, KSMs of potential anticancer and antivirals.Seeing the
trend of the drug approvals for the last 5 years most of the revenue as per US ,EU and worldwide sales comes
from onco, antivirals, antidiabetic and followed by cardiovascular, neuro.

INDUSTRY INSIGHTS
Market size and Supply Chain - Indian pharmaceutical Pharma Industry trends and growth - Pharma group
sector supplies over 50% of the global demand for members are developing the roadmap to implement
various vaccines, 40% of the generic demand for the US Pharma 4.0 model in the future which will enable faster
and 25% of all medicines for the UK. decision making.In the last five years , investment in
● Indian drug & pharmaceutical exports stood at US$ these fields have doubled in size with a future
2,119.08 million in June 2022. projection of over 30% increase by 2025.
● Expectation-Rs. 37,000 crore (US$ 4.83 billion) has
been allocated to the 'National Health Mission.
Schemes initiated- To achieve self-reliance and
According to the Indian Economic Survey 2021,The
minimise import dependency on the country's essential
domestic market is expected to grow 3x in the next
bulk drugs, the Department of Pharmaceuticals
decade.
initiated a PLI scheme to promote domestic
● India's API industry is ranked as the third largest in the
manufacturing by setting up greenfield plants with
world, and the country contributes approximately 57
minimum domestic value addition in four separates
per cent of APIs to the WHO prequalified list of the
'Target Segments' with a cumulative outlay of Rs. 6,940
WHO.
crores (US$ 951.27 million) from FY21 to FY30.
● The Indian API Industry market is estimated to witness
a high CAGR during the forecast period (2020-2026).
FINANCIAL SUMMARY

OUR CLIENTS
 GROWTH PLAN
20CR Working
ASK Capital

20
CRORES
15CR
R&D

Working Capital R&D 5CR

15CR 5CR
FAIR VALUE
Computed the Value of Equity Shares of Susaah Laboratories Pvt. Ltd
based on Discounted Cash Flow Method, which is mentioned below
R VALU
AI

E
F
The Total Value of Susaah Laboratories Pvt Ltd is 4,592.09 Lakhs,
having 1,30,00,000 equity shares at the fae value face Rs10/-each.
` 35
The fair value of one Equity shares having a face value of Rs.10/-
each is Rs.35/- (Thirty-five rupees only)

** Contact Us for a Detailed Fair Value Report

HOW TO INVEST IN 3 STEPS

1 2 3
KYC Payment to be On receipt of payment to
made towards G.A. CM, stocks to be
G.A Capital Management transferred to
Private Limited clients demat a/c

Required Documents
IN I M U M Investment time
• Pan Card • Aadhar Card M
frame will be a period of
• Demat a/c details - (CML Copy)
• Bank Details
`
10 Lakhs 12-18 months
DISCLAIMER
This document has been distributed by G.A Capital Management Private Limited On a strictly
confidential basis. It has been prepared exclusively for the benefit and internal use of the
recipient and does not carry any right of reproduction or disclosure. The information and
projections contained herein can not be disclosed, reproduced or used in whole or in part
without the express prior written permission of G A Capital management.

G.A Capital Management Private Limited makes every effort to use reliable comprehensive
information, but makes no representations or warranties, express or implied or assumes
any liability for the accuracy, completeness, or usefulness of any information contained in
this document. G A Capital Management, its directors, employees and agents will not be
liable for any direct, indirect, incidental or consequential damages sustained or incurred in
connection with the use, operation, or inability to use, or reliance on the information
contained in this document

CORPORATE OFFICE MANUFACTURING UNITS (ISO 9001:2008) & (GMP Facility)

#202, Shashank Residency, Srinivasa Nagar Colony Plot No.7B, Phase-II, Industrial Park
Opp Radhika Theatre, ECIL, Kapra Nadikudi, Dachepalli
Hyderabad - 500 062, Telangana, India Guntur – 522 414, Andhra Pradesh, India

For Investment Enquiries

G.A CAPITAL MANAGEMENT PRIVATE LIMITED

Kura Towers, 1-11-254 & 255, 9th Floor, Sardar Patel Road,
Motilal Nehru Nagar, Begumpet, Hyderabad,Telangana 500016
Email: contact@gacap.com | Web: www.gacap.com
Mobile No: +91 91549 04686